PE20020082A1 - PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1) - Google Patents
PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1)Info
- Publication number
- PE20020082A1 PE20020082A1 PE2001000328A PE2001000328A PE20020082A1 PE 20020082 A1 PE20020082 A1 PE 20020082A1 PE 2001000328 A PE2001000328 A PE 2001000328A PE 2001000328 A PE2001000328 A PE 2001000328A PE 20020082 A1 PE20020082 A1 PE 20020082A1
- Authority
- PE
- Peru
- Prior art keywords
- angiotensin
- pharmaceutical composition
- composition including
- synthase inhibitor
- receptor antagonist
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 title 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 229960000932 candesartan Drugs 0.000 abstract 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 229960004563 eprosartan Drugs 0.000 abstract 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 abstract 1
- 229960000255 exemestane Drugs 0.000 abstract 1
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004773 losartan Drugs 0.000 abstract 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE AL USO DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) INHIBIDOR DE ALDOSTERONA-SINTASA TAL COMO ANASTROZOL, FADROZOL O SU ENANTIOMERO DE FORMULA II, EXEMESTANO; b) UN ANTAGONISTA DEL RECEPTOR ANGIOTENSINA II AT1 SOLO O COMBINADO CON UN DIURETICO TAL COMO HIDROCLOROTIAZIDA; EL ANTAGONISTA DEL RECEPTOR DE AT1 ES SELECCIONADO DE VALSARTAN, LOSARTAN, CANDESARTAN, EPROSARTAN, IRBESARTAN, EL COMPUESTO DE FORMULA I, ENTRE OTROS Y c) UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION ES UTIL PARA LA PREVENCION O TRATAMIENTO DE HIPERTENSION INSUFICIENCIA CARDIACA CONGESTIVA, ATEROESCLEROSIS, RESISTENCIA A LA INSULINA, DISFUNCION ENDOTELIALIT REFERS TO THE USE OF A PHARMACEUTICAL COMPOSITION INCLUDING: a) ALDOSTERONE SYNTHASE INHIBITOR SUCH AS ANASTROZOL, FADROZOL OR ITS FORMULA II ENANTIOMER, EXEMESTANE; b) AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST ONLY OR IN COMBINATION WITH A DIURETIC SUCH AS HYDROCHLOROTHIAZIDE; THE ANTAGONIST OF THE AT1 RECEPTOR IS SELECTED FROM VALSARTAN, LOSARTAN, CANDESARTAN, EPROSARTAN, IRBESARTAN, THE COMPOUND OF FORMULA I, AMONG OTHERS AND c) A PHARMACEUTICALLY ACCEPTABLE VEHICLE. THE COMPOSITION IS USEFUL FOR THE PREVENTION OR TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS, INSULIN RESISTANCE, ENDOTHELLIAL DYSFUNCTION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19674200P | 2000-04-12 | 2000-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020082A1 true PE20020082A1 (en) | 2002-02-21 |
Family
ID=22726655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000328A PE20020082A1 (en) | 2000-04-12 | 2001-04-10 | PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1) |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1282410A2 (en) |
| JP (1) | JP2003530343A (en) |
| KR (1) | KR20020089437A (en) |
| CN (1) | CN1422152A (en) |
| AR (1) | AR032316A1 (en) |
| AU (2) | AU2001273938B2 (en) |
| BR (1) | BR0110079A (en) |
| CA (1) | CA2405895A1 (en) |
| HU (1) | HUP0301335A3 (en) |
| IL (1) | IL152081A0 (en) |
| MX (1) | MXPA02010091A (en) |
| NO (1) | NO20024920L (en) |
| NZ (1) | NZ521855A (en) |
| PE (1) | PE20020082A1 (en) |
| PL (1) | PL358459A1 (en) |
| RU (1) | RU2002129569A (en) |
| SK (1) | SK14612002A3 (en) |
| WO (1) | WO2001076574A2 (en) |
| ZA (1) | ZA200208204B (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002009683A2 (en) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| US6777443B2 (en) | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US7582662B2 (en) | 2002-12-27 | 2009-09-01 | Takeda Pharmaceutical Company Limited | Body weight gain inhibitor |
| SE0300988D0 (en) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| ITTO20040760A1 (en) * | 2004-11-03 | 2005-02-03 | Uni Degli Studi Del Piemonte | USE OF A CORTICOSTEROID IN ASSOCIATION WITH OTHER ACTIVE PRINCIPLES FOR THE TREATMENT OF VASCULAR STENOSIS AND THE PREVENTION OF VASCULAR RESTENOSIS |
| EP1674080A1 (en) * | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| CN101087589B (en) * | 2004-12-24 | 2013-01-30 | 新梅斯托克尔克公司 | Solid pharmaceutical composition comprising valsartan |
| EP1853261B1 (en) | 2005-03-03 | 2017-01-11 | Universität des Saarlandes | Selective inhibitors of human corticosteroid synthases |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| GT200600381A (en) | 2005-08-25 | 2007-03-28 | ORGANIC COMPOUNDS | |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| KR20120041702A (en) | 2009-05-28 | 2012-05-02 | 노파르티스 아게 | Substituted aminobutyric derivatives as neprilysin inhibitors |
| PT2435409E (en) | 2009-05-28 | 2014-11-05 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| ES2683350T3 (en) | 2011-07-08 | 2018-09-26 | Novartis Ag | Method to treat atherosclerosis in subjects with high triglycerides |
| UY35144A (en) | 2012-11-20 | 2014-06-30 | Novartis Ag | APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT |
| EP2956464B1 (en) | 2013-02-14 | 2018-03-28 | Novartis AG | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
| JP2016527249A (en) | 2013-07-25 | 2016-09-08 | ノバルティス アーゲー | Synthetic apelin polypeptide bioconjugates |
| EP3247405B1 (en) | 2015-01-23 | 2019-07-17 | Novartis AG | Synthetic apelin fatty acid conjugates with improved half-life |
| JOP20190086A1 (en) | 2016-10-21 | 2019-04-18 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
| CA3040803A1 (en) | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
| UY38072A (en) | 2018-02-07 | 2019-10-01 | Novartis Ag | COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME |
| EP3787623A1 (en) | 2018-05-03 | 2021-03-10 | Damian Pharma AG | R-fadrozole for use in the treatment of aldostonerism |
| UY38485A (en) | 2018-11-27 | 2020-06-30 | Novartis Ag | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION |
| WO2020110011A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| TW202333563A (en) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (en) | 2021-11-23 | 2024-02-21 | Novartis Ag | NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER |
| US20240391941A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252565A (en) * | 1990-04-02 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Haloethyl-substituted steroid enzyme inhibitors |
| JPH0971586A (en) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | New bicyclic condensed imidazole derivative |
| PT930876E (en) * | 1996-07-22 | 2005-01-31 | Renovo Ltd | USING SEXUAL STEROID FUNCTION MODULATORS FOR TREATING FIBROTIC WOUNDS AND DISORDERS |
| US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
| FR2766821A1 (en) * | 1997-07-29 | 1999-02-05 | Sanofi Sa | 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| ZA991922B (en) * | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
| ES2289814T3 (en) * | 1998-07-10 | 2008-02-01 | Novartis Pharma Ag | ANTIHIPERTENSIVE COMBINATION OF VALSARTAN AND BLOCKER OF CANALES DEL CALCIO. |
-
2001
- 2001-04-10 NZ NZ521855A patent/NZ521855A/en unknown
- 2001-04-10 CA CA002405895A patent/CA2405895A1/en not_active Abandoned
- 2001-04-10 EP EP01940317A patent/EP1282410A2/en not_active Withdrawn
- 2001-04-10 CN CN01807917A patent/CN1422152A/en active Pending
- 2001-04-10 BR BR0110079-3A patent/BR0110079A/en not_active IP Right Cessation
- 2001-04-10 SK SK1461-2002A patent/SK14612002A3/en unknown
- 2001-04-10 KR KR1020027013486A patent/KR20020089437A/en not_active Ceased
- 2001-04-10 HU HU0301335A patent/HUP0301335A3/en unknown
- 2001-04-10 PE PE2001000328A patent/PE20020082A1/en not_active Application Discontinuation
- 2001-04-10 MX MXPA02010091A patent/MXPA02010091A/en not_active Application Discontinuation
- 2001-04-10 AU AU2001273938A patent/AU2001273938B2/en not_active Ceased
- 2001-04-10 IL IL15208101A patent/IL152081A0/en unknown
- 2001-04-10 AU AU7393801A patent/AU7393801A/en active Pending
- 2001-04-10 WO PCT/EP2001/004116 patent/WO2001076574A2/en not_active Application Discontinuation
- 2001-04-10 JP JP2001574092A patent/JP2003530343A/en active Pending
- 2001-04-10 RU RU2002129569/15A patent/RU2002129569A/en not_active Application Discontinuation
- 2001-04-10 AR ARP010101698A patent/AR032316A1/en not_active Application Discontinuation
- 2001-04-10 PL PL01358459A patent/PL358459A1/en not_active Application Discontinuation
-
2002
- 2002-10-11 NO NO20024920A patent/NO20024920L/en not_active Application Discontinuation
- 2002-10-11 ZA ZA200208204A patent/ZA200208204B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1422152A (en) | 2003-06-04 |
| AR032316A1 (en) | 2003-11-05 |
| HUP0301335A2 (en) | 2003-08-28 |
| AU7393801A (en) | 2001-10-23 |
| CA2405895A1 (en) | 2001-10-18 |
| WO2001076574A2 (en) | 2001-10-18 |
| AU2001273938B2 (en) | 2005-03-03 |
| EP1282410A2 (en) | 2003-02-12 |
| KR20020089437A (en) | 2002-11-29 |
| MXPA02010091A (en) | 2003-02-12 |
| JP2003530343A (en) | 2003-10-14 |
| HUP0301335A3 (en) | 2006-02-28 |
| NO20024920D0 (en) | 2002-10-11 |
| SK14612002A3 (en) | 2003-05-02 |
| BR0110079A (en) | 2002-12-31 |
| IL152081A0 (en) | 2003-05-29 |
| NO20024920L (en) | 2002-11-27 |
| RU2002129569A (en) | 2004-03-27 |
| PL358459A1 (en) | 2004-08-09 |
| WO2001076574A3 (en) | 2002-04-25 |
| NZ521855A (en) | 2004-10-29 |
| ZA200208204B (en) | 2003-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020082A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1) | |
| PE20070803A1 (en) | PHARMACEUTICAL COMBINATION OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR | |
| PE107099A1 (en) | COMPOSITION OF ATORVASTATINE AND AN ANTI-HYPERTENSOR | |
| PE20120315A1 (en) | A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE | |
| PE20081557A1 (en) | SUBSTITUTE OXINDOL DERIVATIVES, DRUGS THAT UNDERSTAND THEM, AND THE USE OF THEM | |
| WO2005011646A3 (en) | Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases | |
| MX2009005358A (en) | 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists. | |
| CL2003002731A1 (en) | COMPOUND DERIVED FROM QUINAZOLINE OF DEFINED FORMULA, ACTING AS AN INHIBITOR OF THE AURORA KINASA; COMPOSITE PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND USE OF THE COMPOUND; USEFUL FOR THE TREATMENT OF ENFE | |
| GB2454620A (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
| NO20063380L (en) | Triazole derivatives as vasopressin antagonists | |
| CL2007001870A1 (en) | PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE INCLUDING VALSARTAN, AMLODIPINA, HYDROCHLOROTIAZIDA AND PHARMACEUTICALLY ACCEPTABLE ADDITIVES; PREPARATION PROCEDURE; AND USE FOR THE TREATMENT OF HYPERTENSION, CARDIAC INSUFFICIENCY, INFARTO D | |
| GT200900328A (en) | BENCIMIDAZOL DERIVATIVES | |
| PE20061195A1 (en) | BENZIMIDAZOLE DERIVATIVE AS ANGIOTENSIN II ANTAGONIST | |
| CL2007002689A1 (en) | COMPOUNDS DERIVED FROM PIPERIDIN-1-CARBOXAMIDA, INHIBITORS OF THE RENINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERTENSION, CARDIAC INSUFFICIENCY, CARDIAC FIBROSIS, AMONG OTHERS. | |
| MX2009010297A (en) | Ornithine derivative. | |
| TW200744593A (en) | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery | |
| DOP2010000075A (en) | INHIBITOR COMPOSITE OF GOSPHORILASE GLYCROGEN AND PHARMACEUTICAL COMPOSITION OF THE SAME | |
| PL1843754T3 (en) | New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance | |
| WO2006110884A8 (en) | 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists | |
| WO2008116185A3 (en) | Substituted pyrimidines as adenosine receptor antagonists | |
| EA200901295A1 (en) | CRYSTALLINE 1- (CYCLOGEXYLOXYCARBONYLOXY) ETHYL-1 - (((2'-CYANODYPHENYL-4-IL) METHYL) -2-ETOXY-1H-BENZO [D] IMIDAZOLE-7-CARBOXYLATE and SOFOS | |
| RU2006117790A (en) | APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY | |
| MY144635A (en) | 2-oxo-1,2,4,5-tetrahydro-1,-3-benzodiazepin-3-yl-piperidines used as cgrp antagonists | |
| MX2007004661A (en) | 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists. | |
| AR068814A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING LEVOSIMENDAN AND AN INHIBITOR OF THE CONVERSINE ENZYME OF ANGIOTENSIN (ACE), AND USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |